Welcome to our dedicated page for IRIDEX SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IRIDEX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IRIDEX's regulatory disclosures and financial reporting.
IRIDEX Corporation, an ophthalmic medical technology company, reports that total revenues reached $52.7 million in fiscal 2025, up from $48.7 million in 2024, while net loss narrowed to $4.4 million from $8.9 million. The company sells laser consoles and single-use probes for glaucoma and retinal diseases, leveraging its MicroPulse and Endpoint Management technologies. It relies heavily on international sales and a strategic distribution partnership with Topcon, while facing macroeconomic pressures, regulatory complexity and supply-chain risks. IRIDEX also entered into a $4.0 million convertible note with Novel Inspiration International, with the option for up to $10.0 million in additional notes, adding new debt and potential future equity dilution.
Iridex Corporation reported improving 2025 results with strong Q4 momentum and a return to positive adjusted EBITDA. Fourth quarter revenue reached $14.7 million, up 16% year over year, driven mainly by higher retina system and glaucoma probe sales, plus an extra selling week. Q4 operating expenses fell 10% to $5.5 million, and net loss narrowed to $0.2 million or $0.01 per share.
For full year 2025, revenue grew to $52.7 million from $48.7 million, while operating expenses declined 22% to $21.8 million. Net loss improved to $4.4 million from $8.9 million, and adjusted EBITDA turned positive at $1.1 million versus a $4.3 million loss in 2024. Gross margin was 37%, down from 40%, reflecting higher manufacturing costs and inventory write-downs. Cash and cash equivalents increased to $6.0 million as of January 3, 2026.
For 2026, Iridex forecasts revenue between $51 million and $53 million, which on a pro forma basis excluding Middle East revenue in 2025 represents 1% to 5% growth. The company plans adjusted operating expenses of $19 million to $19.5 million and expects to generate positive operating cash flow for the full year.
IRIDEX Corporation entered into a new triple net lease for its future corporate headquarters at 5215 Hellyer Avenue in San Jose, California. The leased office space totals approximately 30,784 square feet, with the lease term anticipated to begin on July 1, 2026 or when operations commence.
The initial lease term runs for 90 months, with an option to extend for an additional 60 months at the greater of the existing rent or then-prevailing market rent. Annual minimum rent is approximately $646,464 for the first full lease year and approximately $665,857 for the second, then increases about 3% per year.
Minimum rent is abated for six months after the commencement date, but IRIDEX will pay its share of operating expenses, taxes, and utilities under the triple net structure. The agreement includes customary covenants, indemnities, remedies, and rights related to termination, subleasing, and transfers.
IRIDEX Corp’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On March 6, 2026, he bought 1,110 shares of IRIDEX common stock at $1.26 per share. Following this transaction, his direct holdings increased to 121,000 shares.
Dizon Romeo R reported open-market purchase transactions in a Form 4 filing for IRIX. The filing lists transactions totaling 2,200 shares at a weighted average price of $1.34 per share. Following the reported transactions, holdings were 119,890 shares.
IRIDEX Corp’s Chief Financial Officer, Romeo R. Dizon, bought company stock in the open market. On 02/12/2026, he purchased 1,500 shares of IRIDEX common stock at a price of $1.43 per share in a direct transaction.
Following this purchase, Dizon directly beneficially owned 117,690 shares of IRIDEX common stock. The filing records this as an open-market purchase under the standard insider transaction reporting rules.
IRIDEX Corp’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of common stock. On 02/10/2026, he acquired 1,000 shares of IRIDEX common stock at a price of $1.46 per share.
Following this transaction, Dizon directly beneficially owned a total of 116,190 shares of IRIDEX common stock. The filing indicates the ownership is held directly, and the Form 4 was signed on his behalf by attorney-in-fact Nilo De Castro.
IRIDEX Corp's Chief Financial Officer, Romeo R. Dizon, reported a stock purchase in a Form 4 filing. On 02/03/2026, he acquired 2,500 shares of IRIDEX common stock at a price of $1.38 per share. Following this transaction, he directly owns 115,190 common shares.
IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, reported buying additional company stock. On January 29, 2026, he purchased 1,101 shares of common stock at $1.442 per share, bringing his directly held stake to 112,690 shares.
IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On January 28, 2026, he bought 1,300 shares of common stock at $1.46 per share. Following this transaction, he directly owns 111,589 shares of IRIDEX common stock.